Showing 1201-1210 of 1645 results for "".
Muscle MRI for Neuromuscular Disorders
https://practicalneurology.com/diseases-diagnoses/neuromuscular/muscle-mri-for-neuromuscular-disorders/31687/Using muscle MRI to diagnose neuromuscular conditions requires awareness of different patterns of muscle involvement.Team Approach: Enhancing Collaboration in AAD Management
https://practicalneurology.com/programs/cme/team-approach-enhancing-collaboration-in-aad-management/27097/Tune in to learn about diagnosing and treating agitation in Alzheimer’s disease in primary care and long-term care settings.Therapeutic Approaches to Neuromuscular Repeat Disorders: Facioscapulohumeral Muscular Dystrophy and Myotonic Dystrophy Type 1
https://practicalneurology.com/diseases-diagnoses/neuromuscular/therapeutic-approaches-to-neuromuscular-repeat-disorders-facioscapulohumeral-muscular-dystrophy-and-myotonic-dystrophy-type-1/32027/A promising pipeline of therapeutics target toxic RNA.Bruton Tyrosine Kinase Inhibition in Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/bruton-tyrosine-kinase-inhibition-in-multiple-sclerosis/31872/The missing link for treatment optimization?Special Report: Cognitive Screening After COVID-19
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/special-report-cognitive-screening-after-covid-19/31791/Tools are needed for the assessment of neurologic and neuropsychologic sequelae of infection with the SARS-CoV-2 virus.Navigating Therapy: Exploring FDA-Approved Treatments for Effective AAD Care
https://practicalneurology.com/programs/cme/navigating-therapy-exploring-fda-approved-treatments-for-effective-aad-care/27101/Tune in to learn about diagnosing and treating agitation in Alzheimer’s disease in primary care and long-term care settings.Health Care Disparities in Alzheimer Disease Diagnosis and the Use of Amyloid-Targeting Treatments
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/health-care-disparities-in-alzheimer-disease-diagnosis-and-the-use-of-amyloid-targeting-treatments/36240/Disparities in Alzheimer disease care persist, and people from underrepresented racial, ethnic, or socioeconomic groups face considerable barriers to early diagnosis and access to disease-modifying anti-amyloid therapies.- News Briefshttps://practicalneurology.com/columns/practice-management/news-briefs/31327/Thousands of neurologists gathered at the San Diego Convention Center from April 1-8 for the American Academy of Neurology’s (AAN) annual conference, fostering extensive collaboration across subspecialties. Among the key highlights were the release of four new evidence-based practice parameters for
- Lifting the Fog: How to Uncover the Cognitive Effects of AEDshttps://practicalneurology.com/columns/practice-management/lifting-the-fog-how-to-uncover-the-cognitive-effects-of-aeds/31142/Impact of Antiepileptic Drugs on Cognitive and Psychiatric Well-BeingIn the management of epilepsy and migraines, antiepileptic drugs (AEDs) play a crucial role in controlling symptoms. However, the long-term and often lifelong use of AEDs can lead to significant cognitive adverse events (CAE) and p
- Leaving AEDs Behind: When to Withdraw Therapy in Seizure-free Patientshttps://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/pn1008_04-pdf/30980/Managing Antiepileptic Drug (AED) Therapy in Seizure-Free Patients: Key ConsiderationsAchieving complete seizure control is the primary objective in epilepsy management, significantly improving patient quality of life. In specific epilepsy syndromes, such as benign rolandic epilepsy (childhood epile